Abstract
In this report, we studied the side effects of methotrexate (MTX) in patients with ALL who had maintained complete remission with treatment by the 10th or 11th TCLSG protocol. 1 : In vivo administration dose of MTX to ALL patients must be modified in respect to the appearance of liver dysfunction, leukopenia, and exanthema, the necessity of the modification increased according to the clinical course. 2 : MTX concentration in serum at 4 hours after per os administration was observed between 1.3 × 10-7 mol/ml and 5.8 × 10-7 mol/ml. 3 : Effects of MTX on TdR-incorporation were studied on 20 cases and different effects were observed. The effects could be tentatively divided into three groups : TdR-incorporation was increased in 5 cases, decreased in 2 cases, and was not influenced in 13 cases. 4 : Some side effects observed in ALL patients were thought to be induced by allergic reaction according to the clinical signs and the experimental results.
